Inloggen

Login
 
Wachtwoord vergeten?

Curetis 2017

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
677 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 30 31 32 33 34 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
[verwijderd]
0
Cebit 2017: Computational Biologists Predict Antibiotic Resistances Using Biotech

Every year, some 25,000 people die in the European Union from antibiotic-resistant, hard to treat bacteria. Although there are diagnostic methods in place to recognize such resistances in advance, these are typically very time-consuming. Researchers from the Center for Bioinformatics at Saarland University, in cooperation with the molecular diagnostics company Curetis, are developing techniques to uncover these dangerous resistances a lot faster. Their secret weapons: a comprehensive gene database, and powerful algorithms. The researchers will be presenting their rapid test procedures, and their outlook for the future, at Stand E28 at the Cebit computer trade show in Hannover, Germany.

Just a few days ago, the World Health Organization (WHO) published a list of twelve antibiotic-resistant bacterial strains, which are considered to be the "greatest threats to human health".

Andreas Keller, professor for Clinical Bioinformatics at Saarland University, is also studying these bacterial
resistances. “If a patient receives faster access to the treatment best suited to fight the disease in question, it is not only to the benefit of the patient. It also helps dispensing currently available antibiotics in a more targeted manner, so that the development of resistances can be slowed down,” Keller explains.

Existing methods to uncover these resistances in bacterial strains are very time-consuming. First the bacteria are grown in Petri dish nutrient solutions. Once a culture is visible, its response to antibiotics can be tested. But until the result is conclusive, the patient's precious time goes by. “It can take some 24 to 72 hours for the doctor to know for sure which antibiotic to use for the respective treatment. But medical professionals will rarely let a patient suffer for that long, so they tend to rely on their experience,” says the Chief

Commercial Officer of Curetis, Achim Plum. “It's not much use to patients, if doctors pick the wrong antibiotics. What is more, with every antibiotic use, the risk of generating resistant pathogens is increased. And since bacteria multiply very quickly, this is like evolution in time lapse,” says Plum. The company from Southern Germany already offers rapid-test procedures with specialized molecules that detect pathogens, and their specific resistances, for various conditions including pulmonary infections, tissue and transplant infections, and infections of the blood or abdominal cavity.

Plum: “We are currently using genetic markers for antibiotic resistances that have been known for a while. In this manner we can cover the most common resistance mechanisms. But we are also aware that there are still resistances that elude us. This is why we are also trying to decipher those mechanisms that may be uncommon at present, but could become a major threat in future. But in order to develop more efficient test procedures, we need studies of hundreds or thousands of pathogens that have been isolated from patients. We are looking for the complete genetic information of pathogens, as well as their response to common antibiotics, so that we can establish links between antibiotic resistances and the genetic changes that prompted them.”

For this purpose, Curetis acquired the genetic library GEAR (“Genetic Antibiotic Resistance and Susceptibility”) from the Siemens Technology Accelerator in September 2016. The database and associated platform were developed in collaboration with two universities: The Institute of Clinical Molecular Biology in Kiel was responsible for bacterial gene sequencing, while Andreas Keller and his working group on Clinical Bioinformatics at Saarland University focused on the computer-aided data analysis of the 30-terabyte database.

“Bacteria are uncannily clever, and very quick to act upon their genetic predispositions for resistance. Thanks to GEAR, we can now better understand their individual strategies,” says computational biologist Andreas Keller. The foundation of this genetic library is a global database comprising several decades’ worth of information. Currently GEAR contains data on 11,000 bacterial strains, isolated from patient samples from all over the world over the past thirty years, and their?respective reaction patterns to 21 common antibiotics.

With the help of this data, researchers can examine genetic abnormalities associated with certain antibiotic resistances. “It’s like a gigantic puzzle,” Keller says, and quickly extrapolates that the data collected is equivalent to about 500,000 Bibles. But his algorithms and first results give him confidence: “We can already accurately predict resistances 85 percent of the time.”

Resistances develop dynamically, no matter how common or novel the antibiotic in question is. So the GEAR database needs to be adaptable in future as well. “Antibiotic resistance is one of the most urgent health care problems in the world, and research should be well-coordinated. We are planning to expand GEAR into a joint research platform for antibiotic resistances, helping to close the ranks between academic research, public healthcare, and health industry,” says Achim Plum.
Diegy
0
Leeser1959
0
@Diegy; kakel niet elke keer hetzelfde, dat is alleen maar vervuiling van het forum.
Dr. Oogkloot
0
12-04-2017 Curetis: Jaarcijfers 2016
Hierbij zitten ook de cijfers van kw 4 los.
Ben zo benieuwd naar hun vooruitgang vergeleken met vorig jaar.
Ook de mogelijke goedkeuring van Amerika laat niet lang meer op zich wachten..
Aafje Aasgier
0
quote:

Dr. Oogkloot schreef op 17 mrt 2017 om 09:47:


12-04-2017 Curetis: Jaarcijfers 2016
Hierbij zitten ook de cijfers van kw 4 los.
Ben zo benieuwd naar hun vooruitgang vergeleken met vorig jaar.
Ook de mogelijke goedkeuring van Amerika laat niet lang meer op zich wachten..


Dank voor je antwoord Oogkloot. Hopelijk zetten deze triggers de koers in beweging want het is nu een slaapwekkende vertoning.
[verwijderd]
0
quote:

Aafje Aasgier schreef op 17 mrt 2017 om 09:28:


Wanneer komt Curetis met de cijfers?


Wees je er van bewust dat Curetis de belangrijkste cijfers al heeft gepubliceerd:

The Company also reported preliminary unaudited full-year 2016 revenues of EUR 1.3 M and year-end liquidity (cash, cash equivalents and VAT refund receivable) of EUR 24 M. The underlying product revenue (excluding 2015 non-recurring revenues of EUR 0.9 M in system sales to Asian partners for clinical trials and regulatory clearances and EUR 0.3 M of pharma revenue) grew from 0.9M EUR in 2015 to EUR 1.3M in 2016 or by ca.44%. The year-end cash position does not include any amounts under the EUR 25m EIB debt facility announced on 12 December 2016, which remains undrawn to date.

En ook dat ze al hebben gezegd dat er vanwege meer cartridges en vanwege meer installaties een groeiversnelling komt in 2017:

We expect an increase in commercial conversions to follow in a typical 9 to 12 month sales cycle from new installations,” added Dr. Achim Plum, CCO of Curetis, “Therefore, our assumption is that 2017 cartridge revenues will begin to increase considerably as compared to 2016 once all the new installations are up and running and commercial conversions have been made. We have observed that new users of the Unyvero system typically start with a single cartridge type but broaden their usage to other types of available cartridges as they begin to recognize the unique benefits of the Unyvero System. We expect to see similar behavior from new customers as we further expand our installed base.”

www.curetis.com/uploads/tx_news/20170...
Diegy
0
Aafje Aasgier
0
quote:

Diegy schreef op 3 apr 2017 om 13:36:


De laat staat helemaal vol met grote aantallen. Slecht nieuws op komst??


Flapdrol
[verwijderd]
0
Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing

- Successful completion of GEAR asset and know how transfer from Siemens to Curetis

Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 6, 2017 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Company has established Ares Genetics GmbH, a wholly owned subsidiary of Curetis GmbH. Ares Genetics builds on GEAR GEnetic Antibiotic Resistance and Susceptibility Database and associated assets recently acquired for Siemens. The Company will use GEAR to investigate the genetic foundations of antibiotic resistance and develop and subsequently commercialize novel approaches to improve the rapid detection of antibiotic resistance in patients with microbial infections as well as tools to accelerate antibiotic research. Ares Genetics has been established in Vienna, Austria, in close proximity to the Vienna Biocenter VBC and is headed by Dr. Andreas Posch, who has joined Curetis in March from Siemens as Director GEAR & Bio-IT and one of the Managing Directors of Ares Genetics. Dr. Posch headed the bioinformatics activities at Siemens Healthcare and was responsible for GEAR prior to the asset transfer to Curetis. In addition to Dr. Posch, Curetis ´ CCO Dr. Achim Plum will act as a further Managing Director of Ares Genetics.

GEAR contains the entire DNA sequences of more than 11,000 bacterial strains as well as related sensitivity data for 21 antibiotics. The strains were isolated from patient samples at over 200 sites across the world over the last three decades. It is the most comprehensive set of genotype-phenotype combinations for antibiotic resistance today and builds on 30 Terabytes of Next Generation Sequencing (NGS) and drug susceptibility raw data. It allows to assemble and annotate bacterial genomes from NGS raw data, identify genetic variations in those genomes and correlate them with the response of the respective bacterial strain to antibiotics. GEAR was developed and compiled by Siemens in collaboration with two academic partners, the Institute of Clinical Molecular Biology (IKMB) at Kiel University and the Clinical Bioinformatics Group of Saarland University headed by Prof. Dr. Andreas Keller who will continue working with Curetis as a key academic partner to further develop GEAR and investigate the genetics of antibiotic resistance.

Via its subsidiary Ares Genetics, Curetis will use GEAR as a biomarker engine to rapidly identify potential novel biomarkers, biomarker combinations, and algorithms predicting antibiotic resistance, as well as potential novel targets for antimicrobial drugs. In the future, GEAR may also pave the way towards fully genetic antibiograms and provide a reference for NGS-based clinical diagnostics.

“We are planning to leverage GEAR as a source for novel genetic markers to further improve the accuracy of rapid genetic tests for antibiotic resistance in life-threatening infections,” said Dr. Achim Plum, CCO of Curetis and the second Managing Director at Ares Genetics. “GEAR is a perfect fit for Curetis and will allow us to stay on top of the development of novel resistances.”

“GEAR will expand Curetis' content leadership with novel antibiotic resistance markers and form the basis for additional business, including clinical decision support, pharma research or next-generation sequencing interpretation services,” said Dr. Andreas Posch, Managing Director at Ares Genetics. “We will pursue a partnership-based model for future R&D and commercialization. Our goal is to advance GEAR as a collaborative research platform for academic and translational research, public health, and industry partners. This will establish GEAR as the enabling technology platform for a broad and effective alliance against antibiotic resistances.”
To this end, the newly founded company is currently putting together a strong core team of bioinformatics expertise and life science project management to lead and coordinate all GEAR related R&D within the Curetis Group as well as collaborative projects with partners in industry and academia.

To demonstrate the potential of GEAR in our understanding of the genetics of resistance and to attract further partners in the clinical and scientific communities, Curetis together with its leading academic partners from the Clinical Bioinformatics Group of Saarland University is pursuing a comprehensive publication strategy to share numerous aspects of the data set.

“Together with Prof. Keller and our partners at Saarland University, we have already published a first paper on the accuracy of species identification using NGS data and further publications on genetic factors of resistances are in the pipeline. Following the publications, we also intend to make certain aspects of the GEAR database publicly available to stimulate our engagement with the relevant academic communities”, commented Dr. Posch.
Aafje Aasgier
0
quote:

AnalytischDenker schreef op 6 apr 2017 om 09:15:


Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing

- Successful completion of GEAR asset and know how transfer from Siemens to Curetis

Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 6, 2017 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Company has established Ares Genetics GmbH, a wholly owned subsidiary of Curetis GmbH. Ares Genetics builds on GEAR GEnetic Antibiotic Resistance and Susceptibility Database and associated assets recently acquired for Siemens. The Company will use GEAR to investigate the genetic foundations of antibiotic resistance and develop and subsequently commercialize novel approaches to improve the rapid detection of antibiotic resistance in patients with microbial infections as well as tools to accelerate antibiotic research. Ares Genetics has been established in Vienna, Austria, in close proximity to the Vienna Biocenter VBC and is headed by Dr. Andreas Posch, who has joined Curetis in March from Siemens as Director GEAR & Bio-IT and one of the Managing Directors of Ares Genetics. Dr. Posch headed the bioinformatics activities at Siemens Healthcare and was responsible for GEAR prior to the asset transfer to Curetis. In addition to Dr. Posch, Curetis ´ CCO Dr. Achim Plum will act as a further Managing Director of Ares Genetics.

GEAR contains the entire DNA sequences of more than 11,000 bacterial strains as well as related sensitivity data for 21 antibiotics. The strains were isolated from patient samples at over 200 sites across the world over the last three decades. It is the most comprehensive set of genotype-phenotype combinations for antibiotic resistance today and builds on 30 Terabytes of Next Generation Sequencing (NGS) and drug susceptibility raw data. It allows to assemble and annotate bacterial genomes from NGS raw data, identify genetic variations in those genomes and correlate them with the response of the respective bacterial strain to antibiotics. GEAR was developed and compiled by Siemens in collaboration with two academic partners, the Institute of Clinical Molecular Biology (IKMB) at Kiel University and the Clinical Bioinformatics Group of Saarland University headed by Prof. Dr. Andreas Keller who will continue working with Curetis as a key academic partner to further develop GEAR and investigate the genetics of antibiotic resistance.

Via its subsidiary Ares Genetics, Curetis will use GEAR as a biomarker engine to rapidly identify potential novel biomarkers, biomarker combinations, and algorithms predicting antibiotic resistance, as well as potential novel targets for antimicrobial drugs. In the future, GEAR may also pave the way towards fully genetic antibiograms and provide a reference for NGS-based clinical diagnostics.

“We are planning to leverage GEAR as a source for novel genetic markers to further improve the accuracy of rapid genetic tests for antibiotic resistance in life-threatening infections,” said Dr. Achim Plum, CCO of Curetis and the second Managing Director at Ares Genetics. “GEAR is a perfect fit for Curetis and will allow us to stay on top of the development of novel resistances.”

“GEAR will expand Curetis' content leadership with novel antibiotic resistance markers and form the basis for additional business, including clinical decision support, pharma research or next-generation sequencing interpretation services,” said Dr. Andreas Posch, Managing Director at Ares Genetics. “We will pursue a partnership-based model for future R&D and commercialization. Our goal is to advance GEAR as a collaborative research platform for academic and translational research, public health, and industry partners. This will establish GEAR as the enabling technology platform for a broad and effective alliance against antibiotic resistances.”
To this end, the newly founded company is currently putting together a strong core team of bioinformatics expertise and life science project management to lead and coordinate all GEAR related R&D within the Curetis Group as well as collaborative projects with partners in industry and academia.

To demonstrate the potential of GEAR in our understanding of the genetics of resistance and to attract further partners in the clinical and scientific communities, Curetis together with its leading academic partners from the Clinical Bioinformatics Group of Saarland University is pursuing a comprehensive publication strategy to share numerous aspects of the data set.

“Together with Prof. Keller and our partners at Saarland University, we have already published a first paper on the accuracy of species identification using NGS data and further publications on genetic factors of resistances are in the pipeline. Following the publications, we also intend to make certain aspects of the GEAR database publicly available to stimulate our engagement with the relevant academic communities”, commented Dr. Posch.



Dank voor het delen AD. Helaas heeft dit nieuws geen enkele invloed op de koers.
zack_
0
Flinke adviezen worden er gegeven,..........toch is er weinig animo om ze op te pakken.

Dit was de laatste: On 05 April 2017 Kevin DeGeeter of Ladenburg Thalmann has initiated coverage and recommended Curetis shares as "buy" at a target price of EUR 10.50 per share.
Ladenburg Thalmann - Kevin DeGeeter - Email: kdegeeter@ladenburg.com


80% bij investeerders;

www.curetis.com/en/investors/share-in...
[verwijderd]
0
quote:

Aafje Aasgier schreef op 6 apr 2017 om 13:31:


[...]

Dank voor het delen AD. Helaas heeft dit nieuws geen enkele invloed op de koers.


De jaarcijfers zullen helaas ook weinig positiefs geven. We weten al dat de omzet slechts € 1,2 miljoen was. En het verlies zal aanzienlijk zijn.

Gelukkig is de kaspositie inclusief financieringsfaciliteit van de EIB ruim voldoende om ook 2017 zonder externe financiering door te komen.

Ik reken dit jaar op een omzetversnelling. Meer type cartridges dus meer per verkoop per installatie en ook meer installaties moeten op een zeker moment als een vliegwiel gaan werken.. En ik hoop dat Curetis bij de jaarcijfers een outlook voor 2017 zal geven.
bulls
0
bulls
0
Curetis to Present Data from Unyvero LRT U.S. FDA Clinical Trial at ASM Microbe

- U.S. data set complemented by recent clinical study data from European hospital

Amsterdam, the Netherlands, and Holzgerlingen, Germany, April 10, 2017 -- Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that significant clinical data updates on its Unyvero System and P55 / LRT cartridge for the diagnosis of pneumonia and lower respiratory tract infections will be presented at ASM Microbe 2017, being held June 1-5 in New Orleans, LA.

Detailed data from Curetis' U.S. FDA clinical study of the Unyvero System and the LRT cartridge for the diagnosis of lower respiratory tract infections will be presented by Dr Matthew Sims, Director, Infectious Diseases Research at Beaumont Research Institute and one of the U.S. FDA study's principal investigators. Dr Sims will present the study during an oral presentation titled Multicenter Evaluation of the Curetis Lower Respiratory Tract Infection Cartridge on the Unyvero-Platform in session 481, "Pneumonia: Novel Epidemiology, Novel Approaches" (June 5, 2017, 12:15-12:30 PM, Room 208).

In addition, Dr Sims will present clinical data from the portion of the study conducted at Beaumont Hospital, Royal Oak, MI. His presentation Potential Impact of Rapid Diagnostics in Management of Suspected Pneumonia, will be given in the session "Antimicrobial and Diagnostic Stewardship" (June 2, 2017, 12:45-2:45 PM, Exhibit Hall D, Exhibit and Poster Hall).

The U.S. data on the P55/LRT cartridge are complemented by recent findings of researchers at the Institute of Medical Microbiology, University Hospital Essen (Essen, Germany), who published data concluding that the "Unyvero Application is a useful diagnostic tool for the early and rapid detection of pathogens in respiratory specimens". They reported a significantly higher detection rate when using Unyvero as compared to culture methods and a considerably reduced time-to-result, from a median of 48h to a median of 7.5 hours. The team has tested the Unyvero P55 pneumonia application cartridge in daily clinical routine with 439 respiratory specimens of 342 patients. Results from the European Study were presented during this year's 5th Joint Conference of the DGHM & VAAM / VAAM Annual Meeting 2017 and published in Schmidt D et al., Early and Rapid Detection of Respiratory Pathogens: A Commercial Multiplex PCR Assay in Comparison with Culture. Biospektrum Abstractbook Microbiology and Infection 2017, Heidelberg 2017, p. 131 - DOI: 10.1007/s12268-017-0772-x).

"We are excited that new clinical data on our Unyvero P55 / LRT cartridges, which are in line with our findings from various CE performance evaluation studies, have been published in this peer-reviewed format," said Johannes Bacher, COO of Curetis. "They demonstrate the performance of Unyvero in terms of sensitivity and specificity, and also confirm the substantial advantage in terms of time-to-results. Moreover, we are proud that the data from our U.S. FDA trial were selected for an oral presentation at the upcoming ASM Microbe meeting.
He added that new studies are upcoming in the U.S. and the EU to further investigate clinical benefit and impact of the Unyvero P55/LRT cartridge.

###
677 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 ... 30 31 32 33 34 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Curetis Meer »

Koers 0,270   Verschil -0,01 (-4,26%)
Laag 0,270   Volume 240.132
Hoog 0,285   Gem. Volume 262.357
18-okt-19 17:35
label premium

Lucht voor Curetis

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium